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Introduction:
1 Asthma is a common respiratory disease characterised by acute episodes of 2 breathlessness, chronic inflammation of the airways, reversible airflow obstruction 3 and increased airway hyper-responsiveness to a variety of environmental stimuli and 4 allergens (1) . Asthma is a complex disease with a large degree of heterogeneity in 5 the age of onset, the nature of triggers, the severity of symptoms and the 6 contribution of atopy. There is now compelling evidence that asthma is effected by 7 the joint action of both genetic and environmental risk factors in addition to their main 8 effects (2). It affects both children and adults and commonly exists with comorbidities 9 including other allergic diseases such as Allergic Rhinitis (AR) and Atopic Dermatitis 10 (AD), which also have substantial heritability (3). Genome-wide association studies 11 (GWAS), which involve the testing of typically 500,000+ genetic variants for 12 association with the disease, are currently the preferred method for studying 13 complex multifactorial diseases such as asthma.
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In this review, we discuss recent advances in our understanding of the genetic basis 
Asthma is a complex genetic disorder

21
It has been known for over 100 years that asthma and atopic diseases asthma run in identifying a significant concordance of asthma that is higher in monozygotic twins 28 (identical genotype) than in dizygotic twins (on average sharing half of their genes).
29
A recent study using 25,306 twins aged 9 or 12 years identified the heritability of 30 childhood asthma to be 82%(6). Overall genetic factors are thought to account for 31 60-80% of the susceptibility to develop asthma with a smaller effect attributable to 32 environmental factors, however this does not preclude that the environment is 33 important.
34
Therefore, asthma is considered a complex genetic disorder and, in contrast to prevalence between rural/farming and city/non-farming children which cannot be 10 driven by genetic factors alone (7) . This complex mode of inheritance, combined with 11 the heterogeneity in the presentation of the disease and differing environmental 12 influences has made gene discovery in asthma a challenge. See also DOI: PCDH1, HLAG, NPSR1, PHF11, PLAUR, ADAM33, 24 IL10, CD14, IL4, IL13, ADRB2, TNFA, FCER1B, INPP4A, 25 STAT6 and IL4RA providing a novel insight into asthma biology (For excellent 26 reviews see (8, 9) ).
27
Our understanding of the complexity of genetic variation present in the human insertions, and expansions of tandem repeats also represent significant variation. In the following sections we provide an overview of current findings of recent GWAS 4 for i) self-reported/doctor diagnosed asthma and ii) asthma that has been refined 5 clinically to a specific sub-population of asthma patients, namely; childhood onset 6 asthma, severe asthma, asthma with frequent exacerbation, asthma with co-7 morbidities, including allergic rhinitis, atopy, COPD and gender specific analyses. 
24
Recently a role for ORMDL3 in eosinophil trafficking and degranulation, mechanisms 25 thought to be important in asthma, has been identified (15).
26
There are now more than 50 studies registered with the NHGRI-EBI catalog of 27 published GWAS for asthma and related traits (16). Typically, these studies include 28 between 300-2,000 asthma subjects and therefore may be anticipated to identify 29~5 0% of associations for common variants (minor allele frequency 10-50%) (17). A 30 summary of the main findings from these asthma GWAS is shown in Table 1 could be explained by the loci identified in this study (11).
22
Insert Table 1 here.
23
Clinical refinement of asthma for GWAS
24
There is accumulating evidence that asthma is a heterogeneous condition involving (19) (20) (21) . A recent study combined this clustering of phenotypic information 30 in 3,001 asthma subjects to identify four asthma groups and then completed a 31 GWAS which identified novel genetic associations for i) active adult-onset non-32 allergic asthma and CD200 and ii) inactive/mild non-allergic asthma with GRIK2 (22).
33
Of these sub-groups, asthma age of onset has emerged as an important phenotype 1 for asthma development. From a genetic perspective, heritability estimates have 2 been shown to be inversely correlated with age of onset , suggesting that in 3 childhood onset disease genetic factors are more important (23). This same study 4 also demonstrated that genetic factors explained 34% of the variation in the age at 5 onset of and environmental factors 66% (23). Also, as a sub-analyses of the 6 GABRIEL study, chromosome 17q21 was identified as a specific locus for childhood 7 onset asthma (11), similarly GWAS of mild-moderate childhood asthma with 8 methacholine sensitivity and moderate-severe childhood asthma identified PDE4D 9 and DENND1B loci respectively ((24, 25) Table 1 ).
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Multiple recent studies have now started to investigate different sub-phenotypes of 11 asthma to try and identify genetic drivers of specific asthma phenotypes. Such 12 phenotypes have included: i) increased asthma exacerbations in patients taking 13 inhaled corticosteroids (26), ii) early childhood asthma with exacerbations (13), iii) in 14 never/low smoking asthma subjects (27) and moderate-severe asthma (12). These 15 studies have identified several variants distinct to those previously reported for 16 asthma diagnosis such as CDHR3 for early childhood asthma with exacerbations 17 (13) . Interestingly, for several previously identified regions of interest, the median 18 effect size reported was higher in studies with a refined clinical phenotype, 19 suggesting that interpretation of doctor diagnosed asthma GWAS requires caution.
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However, this is not all together surprising as some loci will be of greater importance 21 for different subsets of asthma patients. This is exemplified in the GWAS for severe 22 asthma with exacerbations were the number of hospitalisations reported positively 23 correlated to the SNP effect sizes, including those in the IL33 locus (e.g. OR 1.32, 24 1.22, 1.47, 1.91 for 2, 3, 4/5 and 6 or more hospitalisations respectively) (13) .
25
Focussing to moderate-severe asthma, a recent UK study did not identify any novel Stratification has also included investigations into co-morbidities commonly 5 associated with asthma such as asthma-COPD (29) and asthma-AR (30) overlap.
6
The presence or absence of these co-morbidities with asthma may be triggered by a Table 1 ).
14 Interestingly, stratification of asthma patients based on gender has recently 15 led to the discovery of novel genetic determinants (31), suggesting that gender- (Rap1GAP2/17p13.3, C6orf118/6q27, ERBB4/2q34, AK057517/2q23.3) and two 21 male loci (IRF1/5q31.1, RAB11FTP2/10q26.11) in multiple ancestry groups (32) .
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Therefore while data generated by GWAS of asthma focussed to specific sub-23 groups of patients is only just emerging, it is clear that these analyses have identified 24 overlapping and distinct genetic loci from asthma diagnosis adding further to the 25 concept that genetics may contribute to the differential expression of asthma (see 26 Figure 3 ).
27
Insert Figure 3 here. populations. In the largest GWAS of asthma in the Japanese population to date, 10 7,171 cases and 27,912 controls were used to identify five loci; 4q31 (USP38-11 GAB1), 5q22 (TSLP), 6p21 (HLA), 10p14 (intergenic) and 12q13 (IKZF4) (33) .
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Overlap with other allergic diseases -the atopic march?
14
There is accumulating evidence that allergic diseases e.g. asthma, AR, AD and traits overlapping loci may at least in part explain the concept of the "atopic march" e.g.
22
childhood AD leads to an increased risk of developing asthma, as there is 23 overlapping genetic susceptibility to both conditions. It is important to note that there 24 is also clear trait specificity for many loci, most evident for e.g. the FLG locus for AD.
25
Due to the common occurrence of comorbidities it is difficult to define which 26 susceptibility loci are shared or specific. As discussed earlier, there is move to a 27 more comprehensive phenotype definition in asthma genetics including stratification 28 based on co-morbidities. One recent study aimed to address this for asthma and AD 29 by stratifying patients based on AD (all), AD and asthma, and AD (no asthma) (34).
30
Using a cohort of 1,563 childhood onset AD cases and 4,054 controls, five loci were 31 identified as genome wide significant in all subjects; of interest the 1p21 (FLG) and 32 5q31 (RAD50/IL13) loci achieved markedly greater significance in the AD plus asthma compared to the AD (no asthma) group (34). More recently, a GWAS in (39).
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Of note is that, for the majority of asthma susceptibility loci identified to date it patients. This shift in focus is at least in part driven by the greater appreciation that 26 asthma is heterogeneous and while very large numbers have been able to identify 27 the "low hanging fruit" future approaches need to be focussed to asthma patients 28 with more thorough clinical characterisation. evidence that the epigenome may be important in allergic diseases such as asthma.
22
Recently, a genome-wide methylation association study identified a significant 23 contribution of CpG islands in determining serum IgE levels, a major driver of 24 multiple allergic diseases including allergic asthma (45).
25
In summary, future approaches to asthma gene discovery and translation will 
